CN1144088A - Colading sticking sheet and nicotine sticking sheet compound smoking stopping method - Google Patents
Colading sticking sheet and nicotine sticking sheet compound smoking stopping method Download PDFInfo
- Publication number
- CN1144088A CN1144088A CN 96103216 CN96103216A CN1144088A CN 1144088 A CN1144088 A CN 1144088A CN 96103216 CN96103216 CN 96103216 CN 96103216 A CN96103216 A CN 96103216A CN 1144088 A CN1144088 A CN 1144088A
- Authority
- CN
- China
- Prior art keywords
- nicotine
- patch
- clonidine
- smoking
- sticking sheet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The method for giving up smoking by simultaneously using clonidine transdermal preparation (paster) and nicotine transdermal preparation (paster) is characterized by combining control of release quantity of clonidine paster (control of occurrence extent of nicotine abstinence syndrome) with regulation of release quantity of nicotine paster (regulation of nicotine abstinence extent). Their release quantities are gradually reduced, so that it can quickly, effectively, conveniently and comfortably eliminate nicotine dependence so as to attain the goal of giving up smoking.
Description
The present invention relates to the medicine clonidine of two kinds of different pharmacological actions of compound employing simultaneously and nicotine and all adopts novel transdermal administration (paster) mode, bring into play the different mechanisms of its aiding smoking cessation (elimination nicotine dependence) separately, thereby make the ES fast, effectively, conveniently, cosily reach the smoking cessation purpose of eradicating nicotine dependence.
Harmfulness of smoking health and even life.Current smoking cessation tide has swept across American-European continent.Tobacco Control has been world today's main trend with smoking cessation, has become country's civilization and progressive another important symbol.But the aiding smoking cessation person reaches method and the medicament of eradicating nicotine dependence effectively and quickly still to pay wanting.
In recent years, external large-scale promotion is used Nicotine replacement therapy (comprising nicotine patch) smoking cessation (just there were 5,000,000 human nicotine patch method of giving up smokings in the U.S. in 1992) separately.To the craving for tobacco severe patient, though can accomplish not smoking separately.But when nicotine patch dose (burst size) when reducing, many people still bear serious withdrawal syndrome that can't stand that nicotine dependence causes.The result can only make smoking cessation failure or long-term with the alternative smoking of more heavy dose of nicotine patch, continues to keep it to nicotine dependence, and does not accomplish to reduce or eradicate nicotine dependence (being Nicotine Free) all the time.Therefore the course of treatment of nicotine patch smoking cessation is than long and success rate and little (generally about 10-30%).The literature review of relevant this respect can be consulted: M.L.Gora:Nicotine Transdermal systems, Annals ofPharmacotherapy.v.27 is (1993) p.742-750
Except that Nicotine replacement therapy, when adopting the Clonidine Patch smoking cessation separately both at home and abroad, all can accomplish obviously to alleviate the symptom of nicotine withdrawal syndrome, just alleviate craving for tobacco, but craving for tobacco still is difficult to eliminate fully, remove the person of being resolute in one's determination and can adhere to not smoking, many people still need smoke a small amount of keeping every day.The current paper summary of relevant this respect can be consulted: S.G.Gourlay:Is Clonidine an Effective Smoking cessation Therapy.Drugs.v.50 (2) 197-207 (1995)
No matter use the sort of paster or method aiding smoking cessation, the first step at first will make the ES that the long term the sort of condition response type habitual movement that stops to smoke is arranged.With nicotine patch reach stop to smoke after, must gradually reduce nicotine replacement dosage until fully without nicotine.Must under the situation of eradicating nicotine, (neither smoke) at last in a word, and keep the long term with the dependency of withdrawal to nicotine also without nicotine patch.Could reach the purpose of smoking cessation at last.
Because clonidine has the pharmacological action that alleviates the nicotine withdrawal syndrome, behind the use Clonidine Patch, craving for tobacco must alleviate, and just can more easily reach fully with the nicotine in the alternative Nicotiana tabacum L. of smaller dose nicotine patch simultaneously and not smoke.Keep a period of time like this, after the action of elimination tobacco habit; Further reduce again until without nicotine patch.Because clonidine has alleviated the nicotine withdrawal syndrome, just accomplish easily so reduce nicotine replacement dosage.At last under the situation without nicotine fully, keep the long period and gradually reduce clonidine dosage, until fully without clonidine.So just can fast, effectively, conveniently, cosily reach the smoking cessation purpose of eradicating nicotine dependence.Clinical verification adopts Clonidine Patch and its success rate of the compound aiding smoking cessation of nicotine patch up to record-breaking 80%.The course of treatment, required time only was to use about half of nicotine patch separately.
Adopting control nicotine withdrawal syndrome the Clonidine Patch of degree to occur just can be under the situation with less nicotine replacement dosage with the new smoking abstention method of the just compound use of nicotine patch of what adjusting nicotine withdrawal degree, just can accomplish to stop fully smoking, and the further minimizing nicotine replacement dosage that is easy to do, until eradicating nicotine dependence fully.
According to above-mentioned analysis and Therapeutic Principle, the present invention is described in further detail below by embodiment.1. at first the principle according to principle and Therapeutic Method of above-mentioned combination therapy is explained clearly to firm aspiration ES, so that cooperate with on one's own initiative, and just what ES oneself grasps flexibly.Begin to give up smoking afternoon before that day with the clonidine burst size be every day the 0.2mg Clonidine Patch paste front or the upper arm part that what is cleaned.3. day play (promptly pasting the next day of Clonidine Patch) and just should not smoke beginning smoking cessation.Just nicotine patch is pasted the what front before getting up this early morning.Smoking every day surpasses 20 persons, and to paste the nicotine burst size be 15mg/16 hour nicotine patch; Smoking every day surpasses 10 persons, and to paste the nicotine burst size be 10mg/16 hour nicotine patch; Just before going to bed nicotine patch was taken off evening on the same day and to folding, placed in the former bag, abandoned what child and domestic animal place can't be obtained.Keep nicotine-free paster in bed, in order to avoid nicotine influence sleep.4. paster replacing method: nicotine patch effective time is 16 hours (be daytime wake-up time effective), the new nicotine patch of just should exchangining cards containing all personal details and become sworn brothers before getting up every day, according to my situation, as might just gradually reducing nicotine patch area (two to three days reduce 5mg/16 hour), until not pasting nicotine patch fully.Importantly must maintenance not smoke.Do not smoke can not adhering to strictly according to the facts, can not reduce the nicotine patch area, also can stick on Clonidine Patch (at every turn increasing the Clonidine Patch of 0.1mg burst size every day) in case of necessity or increase 5mg/16 hour nicotine patch.5. the Clonidine Patch new film of just should exchangining cards containing all personal details and become sworn brothers after per 7 days after not pasting nicotine patch fully, should gradually reduce Clonidine Patch amount (generally answer one to two week of what back reduce 0.1mg/ days) according to my situation.Use nicotine patch as still pasting, just can not reduce Clonidine Patch, and should at first reduce or without nicotine patch.6. adhering under the prerequisite of non-smoking,, last a slice Clonidine Patch can not pasted usefulness yet not pasting cigarette subsides back 2-4 week fully.7. the ES has finished recent smoking cessation task.Which kind of 8., resolutely refuse to smoke no matter as later inducement, when thinking smoking again, must contain oneself.Really at need, can paste Clonidine Patch again, with the compacting craving for tobacco with 0.2mg burst size every day.And adhere to trading in weekly, continue to reduce the Clonidine Patch burst size again or stop paster after 4 weeks.In a word must be able to not revert to take drugs again smoking.
More than be typical clinical task instruction principle, concrete using dosage and each step blanking time etc. should suitably be adjusted according to mentioned above principle and ES personal considerations.
Claims (1)
1. the smoking abstention method of clonidine percutaneous plaster and the compound use of nicotine percutaneous plaster is characterized in that:
(1) controls Clonidine Patch burst size (degree appears in control nicotine withdrawal syndrome) and regulate the method that nicotine patch burst size (regulating the nicotine withdrawal degree) combines.
(2) two kinds of medicines of clonidine and nicotine all adopt the transdermal administration mode.
(3) burst size of Clonidine Patch and nicotine patch all adopts the method that gradually reduces, and reduces the nicotine patch burst size earlier, and the Clonidine Patch burst size is reduced in the back.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96103216 CN1144088A (en) | 1996-03-11 | 1996-03-11 | Colading sticking sheet and nicotine sticking sheet compound smoking stopping method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96103216 CN1144088A (en) | 1996-03-11 | 1996-03-11 | Colading sticking sheet and nicotine sticking sheet compound smoking stopping method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1144088A true CN1144088A (en) | 1997-03-05 |
Family
ID=5117921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 96103216 Pending CN1144088A (en) | 1996-03-11 | 1996-03-11 | Colading sticking sheet and nicotine sticking sheet compound smoking stopping method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1144088A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488495A (en) * | 2011-12-19 | 2012-06-13 | 陈心广 | Digitalized intelligent evaluation method for nicotine dependence |
| CN106723371A (en) * | 2016-12-13 | 2017-05-31 | 河南中烟工业有限责任公司 | A kind of self-heating cigarette substitute and preparation method thereof |
-
1996
- 1996-03-11 CN CN 96103216 patent/CN1144088A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488495A (en) * | 2011-12-19 | 2012-06-13 | 陈心广 | Digitalized intelligent evaluation method for nicotine dependence |
| CN102488495B (en) * | 2011-12-19 | 2014-09-10 | 陈心广 | Digitalized intelligent evaluation method for nicotine dependence |
| CN106723371A (en) * | 2016-12-13 | 2017-05-31 | 河南中烟工业有限责任公司 | A kind of self-heating cigarette substitute and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rose et al. | Transdermal nicotine facilitates smoking cessation | |
| US5298257A (en) | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | |
| Gourlay et al. | Antismoking products | |
| EA012306B1 (en) | A composition material for transmucosal delivery | |
| US5055478A (en) | Method for stopping smoking | |
| West et al. | Does switching to an ultra-low nicotine cigarette induce nicotine withdrawal effects? | |
| AU782403B2 (en) | Method for reducing or eliminating smoking | |
| Reisinger | Buprenorphine as new treatment for heroin dependence | |
| CN101332258A (en) | Medicine composition with tranquilization function | |
| CN1144088A (en) | Colading sticking sheet and nicotine sticking sheet compound smoking stopping method | |
| CN101516255A (en) | Device for automatic adjustment of the dose of melatonin and/or delivery of melatonin | |
| Müller et al. | The use of transdermal nicotine in smoking cessation | |
| US20100113453A1 (en) | Sublingual Formulations of D-Cycloserine and Methods of Using Same | |
| US5414005A (en) | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | |
| WO2018169387A1 (en) | Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction | |
| Chervinsky | Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis | |
| James et al. | Studies on the control of aldosterone secretion in man | |
| CN101437530A (en) | Aqueous tobacco leaf extract, uses thereof in the treatment of dependence | |
| US5334390A (en) | Method for tabacco dehabituation | |
| Siegel et al. | Cocaine self-administration in monkeys by chewing and smoking | |
| Munch et al. | An open comparison of dosage frequencies of beclomethasone dipropionate in seasonal allergic rhinitis | |
| Scutt et al. | Stimulation of human fibroblast collagen synthesis in vitro by γ-aminobutyric acid | |
| Marson | Posterior pituitary snuff treatment of nocturnal enuresis | |
| Siegel | Corticosteroids and ACTH in the management of the atopic child | |
| CA2174747A1 (en) | Use of lobeline for the treatment of nicotine withdrawal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: BEIJING CHLEPSIDRAE THERPEUTIC SYSTEMS CO. LTD. TO: BEIJING 39 KELAISIRUICONTROLLED RELEASE PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: No. 1, 2, 53, north, Beijing, Zhongguancun Applicant after: 39 Beijing kelaisirui controlled release pharmaceutical Co Ltd Address before: No. 2732 box 12, Beijing Applicant before: Beijing Kelaisirui Controlled Release Pharmaceutical Co., Ltd. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |